Parkinson disease (Q36319286)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Parkinson disease	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Parkinson disease. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Parkinson's disease

1 reference

based on heuristic

inferred from title

Glenda Halliday

object named as

Glenda M Halliday

4

0 references

object named as

Anthony E Lang

8

0 references

1

object named as

Werner Poewe

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

2

object named as

Klaus Seppi

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

5

object named as

Patrik Brundin

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Caroline M Tanner

3

object named as

Caroline M Tanner

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

author name string

Jens Volkmann

6

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Anette-Eleonore Schrag

7

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

publication date

23 March 2017

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Nature Reviews Disease Primers

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

17013

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Systematic review of incidence studies of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The prevalence of Parkinson's disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Mortality in Parkinson's disease: a 38-year follow-up study

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Socioeconomic variations in the prevalence and incidence of Parkinson's disease: a population-based analysis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Direct medical costs associated with Parkinson's disease: a population-based study

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Epidemiology of Parkinson's disease in Yonago City, Japan: comparison with a study carried out 12 years ago.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Parkinson's disease among American Indians and Alaska natives: a nationwide prevalence study

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The epidemiology of Parkinson's disease: risk factors and prevention

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Neuropathology underlying clinical variability in patients with synucleinopathies

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Ageing and Parkinson's disease: substantia nigra regional selectivity

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Parkinson disease and incidental Lewy body disease: Just a question of time?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Pathological roles of α-synuclein in neurological disorders

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The Synaptic Function of α-Synuclein

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Controlling the mass action of alpha-synuclein in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Proteostasis and aging

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

α-Synuclein and protein degradation systems: a reciprocal relationship

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Research in motion: the enigma of Parkinson's disease pathology spread

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Chaperone-mediated autophagy markers in Parkinson disease brains

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

α-Synuclein impairs macroautophagy: implications for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Lewy body-like α-synuclein aggregates resist degradation and impair macroautophagy

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Progressive decline of glucocerebrosidase in aging and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Survival and dementia in GBA-associated Parkinson's disease: The mutation matters

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

VPS35 mutations in Parkinson disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Analysis of the Retromer complex-WASH complex interaction illuminates new avenues to explore in Parkinson disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for α-Synuclein Degradation and Prevention of Pathogenesis of Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Are synucleinopathies prion-like disorders?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Prion-like transmission of protein aggregates in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

MDS research criteria for prodromal Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The Concept of Prodromal Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

α-Synuclein: the long distance runner

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Mitochondrial dysfunction in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Mitochondrial dysfunction in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Dopamine turnover increases in asymptomatic LRRK2 mutations carriers

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Disease duration and the integrity of the nigrostriatal system in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Spreading of α-synuclein in the face of axonal transport deficits in Parkinson's disease: a speculative synthesis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

DJ-1 modulates mitochondrial response to oxidative stress: clues from a novel diagnosis of PARK7.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Living on the edge with too many mouths to feed: why dopamine neurons die.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Calcium and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Pathogenic lysosomal depletion in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

M1 and M2 immune activation in Parkinson's Disease: Foe and ally?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

How neuroinflammation contributes to neurodegeneration

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Neuroinflammation in Parkinson's disease: a target for neuroprotection?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

LRRK2 modulates microglial activity through regulation of chemokine (C-X3-C) receptor 1 -mediated signalling pathways

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Inflammation and α-synuclein's prion-like behavior in Parkinson's disease--is there a link?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and Cortex

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Reversal of experimental parkinsonism by lesions of the subthalamic nucleus

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Optical deconstruction of parkinsonian neural circuitry

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Therapeutic deep brain stimulation in Parkinsonian rats directly influences motor cortex.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

High-frequency stimulation of the subthalamic nucleus suppresses oscillatory beta activity in patients with Parkinson's disease in parallel with improvement in motor performance.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Reduction in subthalamic 8-35 Hz oscillatory activity correlates with clinical improvement in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Oscillatory pallidal local field potential activity correlates with involuntary EMG in dystonia

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The Cerebral Network of Parkinson's Tremor: An Effective Connectivity fMRI Study

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Where and what is the PPN and what is its role in locomotion?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The diagnosis of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

MDS clinical diagnostic criteria for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

A review of disease progression models of Parkinson's disease and applications in clinical trials

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Dopamine visualized in the basal ganglia of living man.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Imaging insights into basal ganglia function, Parkinson's disease, and dystonia

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Neuroimaging in Parkinson disease: from research setting to clinical practice

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Magnetic resonance imaging as a potential biomarker for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Genetics of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Basic science breaks through: New therapeutic advances in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Unbiased approaches to biomarker discovery in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Toward a redefinition of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Challenges of modifying disease progression in prediagnostic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Technology in Parkinson's disease: Challenges and opportunities

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study).

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Levodopa therapy for Parkinson disease: A look backward and forward

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Novel formulations and modes of delivery of levodopa

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Pharmacological treatment of Parkinson disease: a review

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Therapies in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Impulse control disorders in Parkinson's disease: recent advances

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Subcutaneous apomorphine in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Parkinson's disease: the quintessential neuropsychiatric disorder

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Emerging drugs for autonomic dysfunction in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes; turning tables: should GPi become the preferred DBS target for Parkinson disease? Author response

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Thirty days complication rate following surgery performed for deep-brain-stimulation

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Innovations in deep brain stimulation methodology.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Physical therapy in Parkinson's disease: evolution and future challenges

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Nonpharmacological treatments for patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Does vigorous exercise have a neuroprotective effect in Parkinson disease?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Physical activity and risk of Parkinson's disease in the Swedish National March Cohort.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Physical activities and future risk of Parkinson disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

What contributes to quality of life in patients with Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

New clinical trials for nonmotor manifestations of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Cognitive decline and quality of life in incident Parkinson's disease: The role of attention

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Nonmotor symptoms in nursing home residents with Parkinson's disease: prevalence and effect on quality of life

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Effectiveness of multidisciplinary care for Parkinson's disease: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Predictors of the psychosocial impact of being a carer of people living with Parkinson's disease: a systematic review.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Plasma urate and risk of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Can microbiota research change our understanding of neurodegenerative diseases?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Biomarkers in Parkinson's disease: Advances and strategies

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The diagnostic discrimination of cutaneous α-synuclein deposition in Parkinson disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Cutaneous neuropathy in Parkinson's disease: a window into brain pathology

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Trophic factor gene therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: Where have we been and what have we learned?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: Where do we stand and where must we go next?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Gene therapy for dopamine replacement in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Dyskinesias following neural transplantation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Neuropathology in transplants in Parkinson's disease: implications for disease pathogenesis and the future of cell therapy

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Cell-based therapies for Parkinson disease—past insights and future potential

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

New ISSCR guidelines: clinical translation of stem cell research

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Development of Passive Immunotherapies for Synucleinopathies

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

The progression of pathology in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Identification of TMEM230 mutations in familial Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Launching the movement disorders society genetic mutation database (MDSGene).

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

31 March 2020

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson's disease in a large israeli population

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

7 January 2021

based on heuristic

inferred from DOI database lookup

Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration.

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of oxidative stress in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1038/NRDP.2017.13

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/NRDP.2017.13

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

release_eaxk4ylxbfcbhk6fladxdut4yi

1 reference

https://api.fatcat.wiki/v0/release/eaxk4ylxbfcbhk6fladxdut4yi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36319286&oldid=2198659131"